While the PD-1/PD-L1 axis is a well-established target in immune checkpoint therapy, the IL-33/ST2 signalling pathway has emerged as a novel potential modulator of anti-tumour immunity, with both pro- and anti-tumorigenic roles. This evidence concerns the gene IL33 and neoplasm.